Author:
Li Sheyu,Li Qianrui,Lyu Xiafei,Tian Haoming,Ran Xingwu
Publisher
Springer Science and Business Media LLC
Subject
Physical Therapy, Sports Therapy and Rehabilitation,Orthopedics and Sports Medicine
Reference28 articles.
1. Parmenter BJ, Dieberg G, Smart NA, et al. Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Med. 2015;45(2):231–44.
2. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http://www.cochrane-handbook.org . Accessed 23 Nov 2014.
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.
4. US Food and Drug Administration. FDA drug safety communication: updated risk evaluation and mitigation strategy (REMS) to restrict access to rosiglitazone-containing medicines including Avandia, Avandamet, and Avandaryl. Updated on 18 May 2011. http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm . Accessed 28 Dec 2014.
5. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189–95.